Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy

Launched by SUN YAT-SEN UNIVERSITY · May 11, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treat nasopharyngeal carcinoma, a type of cancer that affects the area behind the nose and throat. Researchers want to see if reducing the amount of radiation used in treatment, after patients receive a specific type of chemotherapy, can help control the cancer better over the long term and improve patients' quality of life. The trial is currently active, meaning it's still ongoing and not recruiting new participants.

To be eligible for this trial, participants must be adults aged 18 to 70 who have been diagnosed with a specific type of nasopharyngeal carcinoma and have not received any prior cancer treatments. They should also be in good overall health, as indicated by a performance score of at least 70, which means they can carry out daily activities with minimal difficulty. Participants will receive three cycles of chemotherapy before undergoing a combination of chemotherapy and radiation therapy. Throughout the trial, researchers will monitor how well the treatment works and any potential side effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • histologic confirmation of nonkeratinizing nasopharyngeal carcinoma; no previous treatment for cancer; nondistant metastatic, newly diagnosed stage III to IVa disease that was staged according to the American Joint Committee on Cancer-Union for International Cancer Control 8th edition stage-classification system; a Karnofsky performance-status score of at least 70 (on a scale from 0 to 100, with lower scores indicating greater disability); planned to receive 3 cycles of Induction Chemotherapy (regimens included docetaxel and cisplatin; docetaxel, cisplatin, and fluorouracil; and gemcitabine and cisplatin); and adequate hematologic, renal, and hepatic function.
• Exclusion Criteria:
• • younger than 18 years or elder than 70 years; receipt of treatment with palliative intent; a history of cancer; receipt of previous treatment (radiotherapy, chemotherapy, or surgery \[except diagnostic procedures\]) to the nasopharynx or neck; lactation or pregnancy; or severe coexisting illness; had disease progress after IC